References
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
- Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmeno-pausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289: 3243–53
- Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362: 419–27
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary pre-vention of coronary disease in postmenopausal women. J Am Med Assoc 1998;280:605–13
- Herrington DM, Reboussin DR, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522–9
- Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839–54
- Naftolin F, Taylor HS, Karas R. Early initiation of hormone therapy and clinical cardio-protection: the Women's Health Initiative ( WHI) could not have detected cardioprotective effects of starting hormone therapy during the meno-pausal transition. Fertil Steril 2004: in press
- Shapiro S. Effects of hormone replacement therapy on the risks of breast cancer and cardio-vascular disease: the validity of the epidemio-logical evidence. In Schneider HPG, Naftolin F, eds. Climacteric Medicine — Where Do We Go? Proceedings of the 4th Workshop of the Inter-national Menopause Society. London: Parthenon Publishing, 2004:in press
- Karas RH, Clarkson TB. Considerations in inter-preting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003; 10:8–12
- Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardio-vascular disease. Ann Intern Med 2000;133: 933–41
- Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone treatment and mortality. N Engl J Med 1997;336:1769–75
- Joakimsen 0, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. J Clin Epidemiol 2000;53: 525–30
- Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530–7
- Mack WJ, Hameed AB, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on athero-sclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 2003;168:91–8
- Adams MR, Kaplan JR, Manuck SB, et al. Inhibi-tion of coronary atherosclerosis by 1713-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10: 1051–7